Traumatic Brain Injury - Pipeline Review, H2 2015 Now Available at iData Insights Traumatic Brain Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Traumatic Brain Injury Pipeline Review, H2 2015 , provides an overview of the Traumatic Brain Injury s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on latestage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124190/traumatic-brain-injury-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124190/traumatic-brain-injury-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Traumatic Brain Injury Overview
1
9 Therapeutics Development 10 Pipeline Products for Traumatic Brain Injury - Overview 10 Pipeline Products for Traumatic Brain Injury - Comparative Analysis 11 Traumatic Brain Injury - Therapeutics under Development by Companies 12 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 17 Traumatic Brain Injury - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Traumatic Brain Injury - Products under Development by Companies 22 Traumatic Brain Injury - Products under Investigation by Universities/Institutes 27 Traumatic Brain Injury - Companies Involved in Therapeutics Development 28 Adamas Pharmaceuticals, Inc. 28 ALSP, Inc. 29 Amarantus Bioscience Holdings, Inc. 30 Athersys, Inc. 31 BHR Pharma, LLC 32 Cognosci, Inc. 33 Euroscreen S.A. 34 Grupo Ferrer Internacional, S.A. 35 International Stem Cell Corporation 36 Io Therapeutics, Inc. 37 Ischemix 38 Karyopharm Therapeutics, Inc. 39 Kyorin Pharmaceutical Co., Ltd. 40 Levolta Pharmaceuticals, Inc. 41 Lixte Biotechnology Holdings, Inc. 42 Lpath, Inc. 43 MandalMed, Inc. 44 Mapreg S.A.S. 45 Mnemosyne Pharmaceuticals, Inc. 46 Neuralstem, Inc. 47 Neuren Pharmaceuticals Limited 48 NeuroHealing Pharmaceuticals Inc. 49 NeuroNascent, Inc. 50 Neuronax SAS
2
51 NeuroVive Pharmaceutical AB 52 Omeros Corporation 53 PharmatrophiX, Inc. 54 Phylogica Limited 55 Prevacus, Inc. 56 PsychoGenics, Inc. 57 QR Pharma, Inc. 58 RAPID Pharmaceuticals AG 59 RegeneRx Biopharmaceuticals, Inc. 60 Remedy Pharmaceuticals, Inc. 61 Sage Therapeutics 62 SanBio, Inc. 63 STATegics, Inc. 64 Tetra Discovery Partners LLC 65 VG Life Sciences, Inc. 66 Traumatic Brain Injury - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 72 Assessment by Route of Administration 75 Assessment by Molecule Type 77 Drug Profiles 79 2-DG - Drug Profile 79 ALP-496 - Drug Profile 81 amantadine hydrochloride ER - Drug Profile 83 AMRS-001 - Drug Profile 85 apomorphine hydrochloride - Drug Profile 88 AST-002 - Drug Profile 90 AVL-8168 - Drug Profile 91 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 92 CHEC-7 - Drug Profile 94 CHEC-9 - Drug Profile 95 CMX-2043 - Drug Profile 97 CNB-001 - Drug Profile 99 COG-1410 - Drug Profile 101 cyclosporine - Drug Profile 103 dexamethasone acetate + melatonin - Drug Profile 107 EPO-Variant - Drug Profile
3
108 ESN-502 - Drug Profile 109 felbamate - Drug Profile 110 FIB-117 - Drug Profile 111 glyburide - Drug Profile 112 HBI-002 - Drug Profile 114 HBI-137 - Drug Profile 115 HBN-1 - Drug Profile 116 HBN-2 - Drug Profile 117 HPI-201 - Drug Profile 118 ibudilast - Drug Profile 120 ICCN-100 - Drug Profile 122 IRX-4204 - Drug Profile 123 ISC-hpNSC - Drug Profile 125 JM-4 - Drug Profile 127 KPT-350 - Drug Profile 128 LB-201 - Drug Profile 129 LB-205 - Drug Profile 130 LM11A-31 - Drug Profile 131 Lpathomab - Drug Profile 132 MAP-4343 - Drug Profile 134 MultiStem - Drug Profile 135 ND-478 - Drug Profile 139 NNI-370 - Drug Profile 140 NNZ-2591 - Drug Profile 141 NSI-189 - Drug Profile 142 NSI-566 - Drug Profile 144 NVP-019 - Drug Profile 146 NVX-428 - Drug Profile 147 NX-210 - Drug Profile 148 PGI-02776 - Drug Profile 149 Posiphen - Drug Profile 151 progesterone - Drug Profile 153 PRV-002 - Drug Profile
4
154 PYC-35 - Drug Profile 155 PYC-36 - Drug Profile 156 PYC-38 - Drug Profile 157 PYC-98 - Drug Profile 158 R-503 - Drug Profile 159 RAP-701 - Drug Profile 161 RGN-352 - Drug Profile 162 SB-623 - Drug Profile 164 sepranolone - Drug Profile 166 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 169 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 170 Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer Profile
s Disease - Drug
171 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 172 Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile 173 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 174 Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile 175 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 176 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 177 Stem Cell Therapy for CNS Disorders - Drug Profile 178 STSE-15 - Drug Profile 179 T-094 - Drug Profile 180 TBI-121 - Drug Profile 181 TBI-122 - Drug Profile 182 TBI-123 - Drug Profile 183 trofinetide - Drug Profile 184 UH-0113 - Drug Profile 186 UH-0213 - Drug Profile 187 VG-1177 - Drug Profile 188 VitalHeme - Drug Profile 190 VOLT-02 - Drug Profile 192 Traumatic Brain Injury - Recent Pipeline Updates 193 Traumatic Brain Injury - Dormant Projects 250 Traumatic Brain Injury - Discontinued Products
5
253 Traumatic Brain Injury - Product Development Milestones 254 Featured News & Press Releases 2 54 Appendix 260 Methodology 260 Coverage 260 Secondary Research 260 Primary Research 260 Expert Panel Validation 260 Contact Us 260 Disclaimer Read More http://www.idatainsights.com/reports-landing-page.php?id=124190/traumatic-brain-injury-pipeline-reviewh2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
6